Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.
Overview
Novo Nordisk (NYSE: NVO) started the GLP-1 weight-loss revolution that is sweeping the world. Its Wegovy/Ozempic shot was so popular that the company couldn't keep up with demand. That proved to be a major problem for the company, particularly after competitor Eli Lilly (NYSE: LLY) introduced its own GLP-1 weight-loss drug, Zepbound/Mounjaro, which enabled greater weight loss.
But Novo Nordisk has been fighting back. Right now, that's all about its Wegovy pill. But a new partnership with Vivani Medical (NASDAQ: VANI) could flip the script on the entire GLP-1 industry.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.